Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases

doi:10.1371/journal.pone.0015384

PLoS One. 2010; 5(11): e15384.

Published online 2010 November 2. doi: 10.1371/journal.pone.0015384

PMCID: PMC2970559

Copyright Coudriet, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases

Gina M. Coudriet,¹ Jing He,² Massimo Trucco,² Wendy M. Mars,¹ and Jon D. Piganelli²^*

¹Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

²Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States of America

Jacques Zimmer, Editor

Centre de Recherche Public de la Santé (CRP-Santé), Luxembourg

* E-mail: jdp51/at/pitt.edu

Conceived and designed the experiments: GMC WMM JDP. Performed the experiments: GMC JH. Analyzed the data: GMC JH WMM JDP. Contributed reagents/materials/analysis tools: MT JDP. Wrote the paper: GMC WMM JDP.

Received August 2, 2010; Accepted September 1, 2010.

This article has been cited by other articles in PMC.

Abstract

The generation of the pro-inflammatory cytokines IL-6, TNF-α, and IL-1β fuel the acute phase response (APR). To maintain body homeostasis, the increase of inflammatory proteins is resolved by acute phase proteins via presently unknown mechanisms. Hepatocyte growth factor (HGF) is transcribed in response to IL-6. Since IL-6 production promotes the generation of HGF and induces the APR, we posited that accumulating HGF might be a likely candidate for quelling excess inflammation under non-pathological conditions. We sought to assess the role of HGF and how it influences the regulation of inflammation utilizing a well-defined model of inflammatory activation, lipopolysaccharide (LPS)-stimulation of bone marrow derived macrophages (BMM). BMM were isolated from C57BL6 mice and were stimulated with LPS in the presence or absence of HGF. When HGF was present, there was a decrease in production of the pro-inflammatory cytokine IL-6, along with an increase in the anti-inflammatory cytokine IL-10. Altered cytokine production correlated with an increase in phosphorylated GSK3β, increased retention of the phosphorylated NFκB p65 subunit in the cytoplasm, and an enhanced interaction between CBP and phospho-CREB. These changes were a direct result of signaling through the HGF receptor, MET, as effects were reversed in the presence of a selective inhibitor of MET (SU11274) or when using BMM from macrophage-specific conditional MET knockout mice. Combined, these data provide compelling evidence that under normal circumstances, HGF acts to suppress the inflammatory response.

Introduction

As a first line of defense in response to infection, tissue injury and stress, macrophages generate the NFκB-dependent pro-inflammatory cytokines, TNF-α, IL-1β and IL-6[1]. The expression of these pro-inflammatory cytokines serves to facilitate the expeditious infiltration of immune cells by rapidly leading to an increase in blood flow and permeability into capillaries. The immune response is tightly regulated and dependent on signaling through ligands binding to Toll-like receptors (TLRs) on the surface of macrophages[2], [3]. Receptor/ligand interaction initiates a signaling cascade that involves the multifaceted enzyme, GSK3β that can then further modulate NFκB activity to transition between the generation of pro- and anti-inflammatory signals[4], [5], [6], [7]. Although necessary and beneficial during infection and tissue injury, the pro-inflammatory cytokine response must be resolved in order to reset the homeostatic threshold and subsequently repair affected tissues in the absence of excess inflammatory mediators[8], [9], [10].

IL-6 induction serves a dual role in the transition between propagation of the inflammatory response and initiation of the APR[9]. The APR serves to reset homeostasis after the ensuing inflammation by mediating the production of acute phase proteins from hepatocytes[8], [11], [12]. These proteins include plasminogen activator inhibitor type 1 (PAI-1) and urokinase plasminogen activator (uPA), both of which are involved in the regulation of hepatocyte growth factor (HGF) activity[12]. IL-6 also promotes HGF transcription and generation of the latent protein[13], [14], [15]. Since IL-6 production both promotes the increased generation of HGF and induces the APR, we hypothesized that accumulating HGF may act to resolve inflammation after stress.

To investigate this hypothesis we sought to assess the role of HGF and its cognate receptor, MET, with regard to innate immune activation of LPS-stimulated BMM. Our results demonstrate that in the presence of HGF there is a significant decrease in the secreted levels of IL-6, suggesting that HGF suppresses inflammation after injury. The suppression of IL-6 is achieved through HGF-dependent inactivation of GSK3β, a powerful governor of inflammatory signaling. This inactivation of GSK3β enhances the anti-inflammatory pathway by promoting the interaction of phospho-CREB with CBP and, occurs in concert with an overall decrease of phospho-p65 (Ser 276) and elevated levels of the anti-inflammatory cytokine IL-10[16], [17], [18], [19], [20]. Hence, our results indicate that HGF is a potent anti-inflammatory agent.

Results

HGF suppresses inflammation in bone marrow-derived macrophages

In order to determine that HGF plays a role in regulating the APR to suppress inflammation, we utilized a well-defined in vitro model of acute inflammation: LPS stimulation of BMM. BMM were cultured with various physiological concentrations of HGF and then stimulated with LPS. Figure 1 demonstrates that 10 pg and 10 ng of HGF exhibit a significant suppression of IL-6 production in LPS-stimulated BMM after 24 hours.

Figure 1

HGF modulates IL-6 production in LPS stimulated macrophages.

Pharmacological inhibition of HGF-MET signaling abolished HGF's suppressive effects in BMM

To further confirm that the inhibition of IL-6 production was a result of HGF signaling, we repeated the in vitro model of acute inflammation, this time in the presence of SU11274, a specific MET inhibitor. An optimal concentration of 1 µM was chosen for the inhibition of signaling in BMM. SU11274[21], [22] was added to BMM cultures 2 hr prior to the addition of HGF and then cultures were stimulated with LPS. The results demonstrate that incubation with the MET inhibitor abolished the inhibitory effect induced by HGF on IL-6 production in BMM stimulated with LPS (Figure 2).

Figure 2

A MET kinase inhibitor abrogates HGF suppression of IL-6.

Conditional deletion of MET-receptor on BMM confirms pharmacological data demonstrating HGF's suppressive effects in BMM

To rule out any offsite pharmacological effects by the MET inhibitor as the cause for the IL-6 inhibition and to further study the important role HGF plays in tempering the acute inflammatory response, conditional MET flox mice specific for the macrophage lineage were generated. Figure 3 demonstrates that BMM isolated from MET conditional knockout mice fail to suppress IL-6 production in response to LPS as compared to their wild type littermate controls. Use of the knockout animals confirmed the results demonstrated with the pharmacological MET inhibitor whereby the suppressive effect of HGF on IL-6 production was significantly reduced as compared with cultures not treated with the inhibitor (Figure 2). Taken together, these results clearly illustrate the interaction of HGF and MET suppresses IL-6, further supporting the important role HGF plays in tempering the acute inflammatory response.

Figure 3

Deletion of the HGF receptor MET demonstrates a reversal in the effects of HGF on LPS stimulated BMM.

HGF suppresses inflammation through GSK3β

To further understand the mechanism in which HGF suppresses the inflammatory response, we looked downstream of HGF-MET signaling at potential regulatory targets. One target, GSK3β, is known to regulate inflammation through activation of NFκB, resulting in pro-inflammatory cytokine production[5], [7], [23], [24], [25], [26]. When GSK3β is in its inactive state (phosphorylated), its influence over NFκB activation is limited and therefore pro-inflammatory cytokine production is quantitatively lessened[5]. GSK3β is known to be a downstream target of HGF[27], [28], [29]. We found that protein lysates prepared from BMM isolated from C57BL6 mice cultured with 10 ng HGF demonstrated an increased in phosphorylated, or inactive GSK3β (Figure 4), supporting the idea that HGF-MET interactions lead to inactivation of GSK3β.

Figure 4

Treatment with HGF leads to increased GSK3β phosphorylation.

HGF signaling leads to the interaction of CBP with phospho-CREB by GSK3β

To further determine the downstream signaling that results from HGF's regulation of GSK3β, we investigated the interaction of NFκB with the co-activator protein (CBP). Interactions between NFκB and CBP are facilitated by activated GSK3β when there is promotion of pro-inflammatory cytokine production[7], [24]. Our data, however, shows that the inhibition of GSK3β following HGF treatment is associated with an increased interaction between CBP and phospho-CREB. Stimulation of BMM with LPS in the presence of HGF led to an increase of phosphorylated (inactive) GSK3β (Ser 9) (Figure 4), which correlated with an increase in CBP-phospho-CREB (Ser 133) interaction (Figure 5A) followed by an increase in the levels of IL-10 production (Figure 5C).

Figure 5

HGF promotes the interaction of phosphorylated CREB with CBP along with an increased production of IL-10.

HGF inhibits the phosphorylation of Ser 276 on p65 of NFκB

The enhanced interaction between CBP and phospho-CREB during the HGF-induced anti-inflammatory response suggests CBP is being sequestered away from NFκB. Normally, the transcriptional activity of NFκB occurs through the phosphorylation of p65 at Serine 276 whereby a conformational change takes place that allows its nuclear association with CBP/p300[30]. This interaction allows for NFκB-dependent transcription of pro-inflammatory cytokines such as IL-6. Figure 6 demonstrates abundant phosphorylation of p65 at Ser 276 in both the nucleus and cytoplasm upon stimulation with LPS alone (Figure 6B). However, with the addition of HGF (10 pg) the overall phosphorylation of p65 is reduced with nuclear localization essentially absent (Figure 6C). Again, the effects of HGF are abrogated when SU11274 is added to the cultures, indicating the suppression is mediated via the HGF receptor, MET (Figure 6D).

Figure 6

HGF prevents the nuclear translocation of phosphorylated p65.

Discussion

IL-6, a key pro-inflammatory cytokine, is upregulated “as a defense mechanism” in order to promote the APR and to initiate homeostasis as quickly as possible after an acute injury. In cases of chronic stress; however, IL-6 changes its role by modulating the leukocytic repertoire resulting in a chronic inflammatory state[9], [11]. Although the presence of IL-6 is imperative during early injury and acute inflammation, contraction of the inflammatory process must occur in order for the system to regain normal homeostasis and to initiate repair. As a result, IL-6 is also posited to possess anti-inflammatory properties. Evidence to support this latter hypothesis is shown by the enhanced inflammatory responses induced following endotoxin exposure to IL-6^−/− mice[9], although, the authors never suggest a biochemical mechanism to explain why this unanticipated phenomenon occurs. HGF, a cytokine widely known for perpetuating liver regeneration, has also been described as having anti-inflammatory properties in cases of persistent inflammation[27], [28], [29], [31], [32], [33]. Importantly, the expression of HGF is induced by IL-6 while its regulation is controlled via acute phase proteins (urokinase and PAI-1) that are also induced following IL-6 stimulation. Hence, we posited a feedback loop wherein the pro-inflammatory properties ascribed to IL-6 are exhibited through induction of the APR and the anti-inflammatory properties are mediated via HGF that is produced in response to IL-6 stimulation.

Using LPS stimulated primary BMM cell cultures as a source of IL-6, we demonstrate that addition of HGF is in fact anti-inflammatory (Figure 1). Furthermore, we are able to confirm that the HGF-MET interaction propagates the suppression of cytokine production by using the pharmacological inhibitor of MET, SU11274 (Figure 2). Other studies have focused on using inhibitors of the PI3K and Akt signaling cascade[4], [7], that are down-stream of HGF-MET signaling; however, by using a direct MET kinase inhibitor as well as the macrophage specific MET floxed mice (Figure 3), we demonstrate that HGF-MET signaling is capable of suppressing inflammation.

Traditionally, GSK3β is known for regulating glycogen synthase and the storage of glycogen into peripheral sites[34], [35], but recent evidence suggests this kinase may also function as a key player in modulating inflammation[7], [17]. It is well known that the activation of NFκB through TLR signaling leads to the transcription of pro-inflammatory cytokines; however, recently data was published indicating that at a more general level, cytokine production is regulated through GSK3β, which in turn regulates NFκB activity[4], [7]. Hence, GSK3β appears to be a pivotal kinase that serves as a nodal point for both the generation and resolution of the inflammatory response[17], [27], [28]. Our data demonstrates that treatment BMM with HGF leads to increased phosphorylation and inactivation of GSK3β (Ser 9) (Figure 4) and that this response is sustained, even in the presence of LPS.

Pharmacological inhibitors of PI3K, Akt, and GSK3β induce inactivation of GSK3β. Inactive GSK3β can then promote the association of phospho-CREB (Ser 133) with CBP and sequester the CBP away from NFκB p65 (Ser 276). These signaling changes are associated with a switch from a pro- to anti-inflammatory pathway with a resultant increase in IL-10 production[7]. Our data shows that using HGF in place of those inhibitors gives similar results. BMM treated with both LPS and HGF demonstrated an increased CBP-phospho-CREB interaction, which was reduced in the presence of the MET kinase inhibitor (Figure 5). Furthermore, there was an increase in the production of IL-10 (Figure 5C) and, a reduction in the nuclear translocation phosphorylated p65. Combined, the data suggest that during an inflammatory response, active HGF may be key in switching the cellular response from a pro- to an anti-inflammatory pathway.

In addition to the canonical pathway, TLR signaling has been shown to weakly activate PI3K. This then leads to anti-inflammatory events by altering the cytokine repertoire[7]. Hence, it has been postulated that PI3K is the point at which TLR signaling is differentiated from a pro-inflammatory to an anti-inflammatory condition. Our data indicates that in the absence of HGF, TLR signaling promotes the phosphorylation of NFκB along with its translocation to the nucleus and that this correlates with the production of the pro-inflammatory cytokine IL-6. In contrast, in the presence of HGF, GSK3β is phosphorylated (inactive) and TLR stimulation leads to production of the anti-inflammatory cytokine, IL-10. Notably, HGF signaling is well known to signal through the PI3K pathway[26], [27], [28], [36]. Hence, we propose that under normal circumstances, induction of IL-6 through pro-inflammatory stimuli leads to the eventual production of HGF[14], [15], [37]. HGF-MET interactions then ultimately result in phosphorylation of GSK3β and in the continued presence pro-inflammatory stimuli, facilitates an increased association of phospho-CREB with CBP. This then suppresses NFκB's transcriptional activity and results in the resolution of the inflammatory response (Figure 7). Our data describe the intimate interaction between IL-6 and HGF in regulation of inflammation. Hence we propose that HGF acts as an internal rheostat regulating the complex cascade of induction and resolution of inflammation (Figure 7).

Figure 7

Proposed mechanism of HGF-mediated suppression.

Materials and Methods

Mouse strains

C57BL/6J and B6.129P2-Lyz2^tm1(cre)Ifo/J mice were purchased from The Jackson Laboratory and the MET floxed mice were a gift from Dr. Snorri Thorgeirsson[38]. B6.129P2-Lyz2^tm1(cre)Ifo/J were crossed with MET floxed mice to produce CRE^lysZ+ MET^+/+ animals. Male mice 6–8 week of age were used as a source of bone marrow-derived macrophages. All animals were housed under specific pathogen-free conditions in the Animal Facility at the University of Pittsburgh. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh (Assurance Number A3187-01).

Isolation of mouse bone marrow derived macrophages

Bone marrow derived macrophages (BMM) were cultured as previously described[39]. Femurs and tibias were dissected from sacrificed mice. Bone marrow cells were flushed from the bones using a 26 g needle until the bone is clear. The cells were then centrifuged and filtered through a cell strainer. Cells were cultured in 10% L929 conditioned media, with a media change every two days. Cultured cells were harvested and stained with the macrophage specific marker F4/80 to assess purity 7 days after isolation. Cells were plated on 24-well tissue culture plates at 1×10⁶ cells/well for supernatant analysis or on 100 cm tissue dishes at 2.5×10⁷ cells/dish for protein analysis.

Preparation of samples for ELISA

BMM plated in 24-well plates were pretreated with recombinant mouse HGF (R&D Systems) for 24 h at 37°C prior to stimulation with 1 µg/ml lipopolysacharride (LPS) from Escherichia coli (055:B5) (Sigma Aldrich) for 24 h. In assays using the MET kinase inhibitor, SU11274 (Calbiochem), BMM were pretreated with 1 µM of the inhibitor for 2 h at 37°C followed by the 24 h HGF incubation and subsequent LPS stimulation. Cell culture supernatants were collected from triplicate wells, pooled and stored at −20°C for further analysis.

Preparation of protein lysates

BMM were prepared as above and cultured in 100 mm dishes. At 15 minutes post-LPS stimulation, the BMM were washed with ice cold PBS and cells were harvested with gentle scraping and centrifugation. Cellular extracts were harvested using RIPA buffer supplemented with phosphatase and protease inhibitor cocktails (Roche) and 1 mM PMSF (Sigma-Aldrich). After the addition of 0.3 ml of lysis buffer, the macrophages were incubated on ice for 20 min, vortexed 3 times and centrifuged for 5 min at maximum speed at 4°C. The supernatant (whole cell lysate) was collected and the protein concentration of the lysates was determined by the bicinchonninic acid (BCA) protein assay according to the manufacturer's instruction (Pierce).

Enzyme linked immunosorbent assay (ELISA)

Supernatants from BMM pretreated with HGF and/or SU11274 and stimulation with LPS were collected at 24 h. IL-6 and IL-10 cytokines secreted by BMM were measured by ELISA using purified capture and biotinylated detection antibody pairs (BD Pharmingen). The ELISA plates were read using a SpectraMax M2 plate reader, and the data was analyzed using SoftMax Pro software (Molecular Devices).

Western immunoblotting

Protein lysates were assayed by Western blot as previously described, with minor exceptions[39]. Anti-phospho-GSK3β (Ser 9), anti-phospho-CREB (Ser 133) and anti-CREB used at 1 [ratio]

1000 from Cell Signaling. Anti-GSK3β was used at 1 [ratio]

1000 from Santa Cruz. Secondary antibodies were used from either Cell Signaling or Jackson ImmunoResearch. Blots were analyzed using the Fujifilm LAS-4000 imager and Multi Gauge software (Fujifilm Life Science).

Immunoprecipitation

1 µg of CBP antibody (Santa Cruz) was added to 100 mg protein from whole cell lysates and incubated at 4°C overnight. The following day, Protein G-conjugated sepharose beads were added to the protein/antibody complex tube and incubated for 2 h. Immunoprecipitates were collected by centrifugation, washed twice with PBS, and then boiled in Laemmli sample buffer. Western blot was performed as described above.

Cytospins

BMMs were washed with PBS and gently scraped from multi-well tissue culture dishes. Cells were collected into centrifuge tubes and spun at high speed for 10 min. Cell pellets were resuspended to 1×10³ cells per ml and cytospins were prepared with 100 µl of cells per slide. Slides were dried and stored at −80°C until staining.

Phospho-NFκB p65 (Ser276) staining

Cytospun slides were fixed in 2% paraformaldehyde for 5 minutes and blocked with 20% non-immune normal goat serum for 1 hour at room temperature. After immune stained with primary antibody (Rabbit anti-Phospho-NFκBp65 (Ser276) 1 [ratio]

100, (Cell Signaling Technology), slides were washed 5 times in PBS and incubated with secondary antibodies Cy3-conjugated goat anti-rabbit (Jackson ImmunoResearch). Nuclear staining (Hoechest staining, Molecular Probes) was performed. Images were viewed at 40x magnification and captured by using a Nikon confocal microscope (Nikon D-ECLIPSE C1, Japan).

Acknowledgments

G.M.C. is a PhD candidate at the University of Pittsburgh and this work is submitted in partial fulfillment of the requirement for the PhD. We thank Snorri Thorgeirsson for the gift of the MET floxed mice, and Dr. Hubert Tse and Meghan Delmastro for critical reading of this manuscript.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by an American Heart Association pre-doctoral award (GMC), a Research Advisory Council pre-doctoral award by Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (GMC), a Juvenile Diabetes Research Foundation (76-01) (JDP), and the American Diabetes Association (CDA 7.07 CD16) (JDP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071. [PubMed]

2. Janeway CA, Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. [PubMed]

3. Medzhitov R, Janeway C., Jr Innate immunity. N Engl J Med. 2000;343:338–344. [PubMed]

4. Vines A, Cahoon S, Goldberg I, Saxena U, Pillarisetti S. Novel anti-inflammatory role for glycogen synthase kinase-3beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1beta-induced inflammatory gene expression. J Biol Chem. 2006;281:16985–16990. [PubMed]

5. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577–595. [PMC free article] [PubMed]

6. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 2010;31:24–31. [PMC free article] [PubMed]

7. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6:777–784. [PMC free article] [PubMed]

8. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454. [PubMed]

9. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311–320. [PMC free article] [PubMed]

10. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453–1464. [PMC free article] [PubMed]

11. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(Suppl 2):S3. [PMC free article] [PubMed]

12. Mars WM, Liu ML, Kitson RP, Goldfarb RH, Gabauer MK, et al. Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology. 1995;21:1695–1701. [PubMed]

13. Li W, Liang X, Leu JI, Kovalovich K, Ciliberto G, et al. Global changes in interleukin-6-dependent gene expression patterns in mouse livers after partial hepatectomy. Hepatology. 2001;33:1377–1386. [PubMed]

14. Liu Y, Michalopoulos GK, Zarnegar R. Structural and functional characterization of the mouse hepatocyte growth factor gene promoter. J Biol Chem. 1994;269:4152–4160. [PubMed]

15. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177–1180. [PMC free article] [PubMed]

16. Gotschel F, Kern C, Lang S, Sparna T, Markmann C, et al. Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp Cell Res. 2008;314:1351–1366. [PubMed]

17. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, et al. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity. 2006;24:563–574. [PubMed]

18. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170–181. [PubMed]

19. Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL-6 and IL-10 balance by HGF via recruitment of heme oxygenase-1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. Int J Mol Med. 2009;24:161–170. [PubMed]

20. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006;108:218–227. [PubMed]

21. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 2004;23:5387–5393. [PubMed]

22. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63:5462–5469. [PubMed]

23. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95–102. [PubMed]

24. Woodgett JR, Ohashi PS. GSK3: an in-Toll-erant protein kinase? Nat Immunol. 2005;6:751–752. [PubMed]

25. Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem. 2003;278:39583–39590. [PubMed]

26. Gong R. Multi-target anti-inflammatory action of hepatocyte growth factor. Curr Opin Investig Drugs. 2008;9:1163–1170. [PubMed]

27. Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, et al. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol. 2008;173:30–41. [PubMed]

28. Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem. 2008;283:7401–7410. [PubMed]

29. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, et al. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol. 2004;15:2868–2881. [PubMed]

30. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1998;1:661–671. [PubMed]

31. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephrol. 2006;17:2464–2473. [PubMed]

32. Homsi E, Janino P, Amano M, Saraiva Camara NO. Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury. Am J Nephrol. 2009;29:283–291. [PubMed]

33. Ito W, Takeda M, Tanabe M, Kihara J, Kato H, et al. Anti-allergic inflammatory effects of hepatocyte growth factor. Int Arch Allergy Immunol. 2008;146(Suppl 1):82–87. [PubMed]

34. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes. 1999;48:1662–1666. [PubMed]

35. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 2000;49:263–271. [PubMed]

36. Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 2006;107:760–768. [PubMed]

37. To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, et al. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol. 2002;27:220–226. [PubMed]

38. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004;101:4477–4482. [PubMed]

39. Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med. 2004;36:233–247. [PubMed]

Articles from PLoS ONE are provided here courtesy of
Public Library of Science